Cargando…

Chimeric aptamers in cancer cell-targeted drug delivery

Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanwar, Jagat R, Roy, Kislay, Kanwar, Rupinder K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233271/
https://www.ncbi.nlm.nih.gov/pubmed/21955150
http://dx.doi.org/10.3109/10409238.2011.614592
_version_ 1782218392683413504
author Kanwar, Jagat R
Roy, Kislay
Kanwar, Rupinder K
author_facet Kanwar, Jagat R
Roy, Kislay
Kanwar, Rupinder K
author_sort Kanwar, Jagat R
collection PubMed
description Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evolution of ligands by exponential enrichment (SELEX), have now been identified as excellent tools for chemical biology, therapeutic delivery, diagnosis, research, and monitoring therapy in real-time imaging. Today, aptamers represent an interesting class of modern Pharmaceuticals which with their low immunogenic potential mimic extend many of the properties of monoclonal antibodies in diagnostics, research, and therapeutics. More recently, chimeric aptamer approach employing many different possible types of chimerization strategies has generated more stable and efficient chimeric aptamers with aptamer-aptamer, aptamer-nonaptamer biomacromolecules (siRNAs, proteins) and aptamer-nanoparticle chimeras. These chimeric aptamers when conjugated with various biomacromolecules like locked nucleic acid (LNA) to potentiate their stability, biodistribution, and targeting efficiency, have facilitated the accurate targeting in preclinical trials. We developed LNA-aptamer (anti-nucleolin and EpCAM) complexes which were loaded in iron-saturated bovine lactofeerin (Fe-blf)-coated dopamine modified surface of superparamagnetic iron oxide (Fe(3)O(4)) nanoparticles (SPIONs). This complex was used to deliver the specific aptamers in tumor cells in a co-culture model of normal and cancer cells. This review focuses on the chimeric aptamers, currently in development that are likely to find future practical applications in concert with other therapeutic molecules and modalities.
format Online
Article
Text
id pubmed-3233271
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Informa Healthcare
record_format MEDLINE/PubMed
spelling pubmed-32332712011-12-08 Chimeric aptamers in cancer cell-targeted drug delivery Kanwar, Jagat R Roy, Kislay Kanwar, Rupinder K Crit Rev Biochem Mol Biol Review Article Aptamers are single-stranded structured oligonucleotides (DNA or RNA) that can bind to a wide range of targets ("apatopes") with high affinity and specificity. These nucleic acid ligands, generated from pools of random-sequence by an in vitro selection process referred to as systematic evolution of ligands by exponential enrichment (SELEX), have now been identified as excellent tools for chemical biology, therapeutic delivery, diagnosis, research, and monitoring therapy in real-time imaging. Today, aptamers represent an interesting class of modern Pharmaceuticals which with their low immunogenic potential mimic extend many of the properties of monoclonal antibodies in diagnostics, research, and therapeutics. More recently, chimeric aptamer approach employing many different possible types of chimerization strategies has generated more stable and efficient chimeric aptamers with aptamer-aptamer, aptamer-nonaptamer biomacromolecules (siRNAs, proteins) and aptamer-nanoparticle chimeras. These chimeric aptamers when conjugated with various biomacromolecules like locked nucleic acid (LNA) to potentiate their stability, biodistribution, and targeting efficiency, have facilitated the accurate targeting in preclinical trials. We developed LNA-aptamer (anti-nucleolin and EpCAM) complexes which were loaded in iron-saturated bovine lactofeerin (Fe-blf)-coated dopamine modified surface of superparamagnetic iron oxide (Fe(3)O(4)) nanoparticles (SPIONs). This complex was used to deliver the specific aptamers in tumor cells in a co-culture model of normal and cancer cells. This review focuses on the chimeric aptamers, currently in development that are likely to find future practical applications in concert with other therapeutic molecules and modalities. Informa Healthcare 2011-12 2011-09-28 /pmc/articles/PMC3233271/ /pubmed/21955150 http://dx.doi.org/10.3109/10409238.2011.614592 Text en © 2011 Informa Healthcare USA, Inc http://creativecommons.org/licenses/by/2.0/ This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Informa Healthcare journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kanwar, Jagat R
Roy, Kislay
Kanwar, Rupinder K
Chimeric aptamers in cancer cell-targeted drug delivery
title Chimeric aptamers in cancer cell-targeted drug delivery
title_full Chimeric aptamers in cancer cell-targeted drug delivery
title_fullStr Chimeric aptamers in cancer cell-targeted drug delivery
title_full_unstemmed Chimeric aptamers in cancer cell-targeted drug delivery
title_short Chimeric aptamers in cancer cell-targeted drug delivery
title_sort chimeric aptamers in cancer cell-targeted drug delivery
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233271/
https://www.ncbi.nlm.nih.gov/pubmed/21955150
http://dx.doi.org/10.3109/10409238.2011.614592
work_keys_str_mv AT kanwarjagatr chimericaptamersincancercelltargeteddrugdelivery
AT roykislay chimericaptamersincancercelltargeteddrugdelivery
AT kanwarrupinderk chimericaptamersincancercelltargeteddrugdelivery